New York State Common Retirement Fund Has $17.44 Million Holdings in Grifols, S.A. (NASDAQ:GRFS)

New York State Common Retirement Fund lifted its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 50.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,452,728 shares of the biotechnology company's stock after acquiring an additional 823,456 shares during the period. New York State Common Retirement Fund owned approximately 0.36% of Grifols worth $17,439,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Ballentine Partners LLC bought a new position in Grifols in the 1st quarter valued at approximately $77,000. Cerity Partners LLC lifted its stake in Grifols by 22.8% in the 1st quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 4,129 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Grifols by 7.6% in the 1st quarter. Envestnet Asset Management Inc. now owns 274,693 shares of the biotechnology company's stock valued at $1,953,000 after purchasing an additional 19,447 shares during the last quarter. Compass Wealth Management LLC bought a new position in Grifols in the 1st quarter valued at approximately $541,000. Finally, Sequoia Financial Advisors LLC lifted its stake in Grifols by 14.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock valued at $186,000 after purchasing an additional 3,399 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently commented on GRFS. Wall Street Zen raised shares of Grifols from a "buy" rating to a "strong-buy" rating in a research note on Monday, July 7th. JPMorgan Chase & Co. increased their price objective on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th.

Grifols Trading Down 1.1%

Shares of GRFS stock traded down $0.11 during trading hours on Friday, hitting $9.94. 796,121 shares of the company's stock traded hands, compared to its average volume of 1,047,924. The stock's 50 day simple moving average is $8.67 and its 200 day simple moving average is $7.82. The stock has a market cap of $6.83 billion, a PE ratio of 8.50, a price-to-earnings-growth ratio of 0.36 and a beta of 0.55. Grifols, S.A. has a 12 month low of $6.19 and a 12 month high of $10.32. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.